Kalvista Drug Delay: FDA Faces Resource Issues
- The Food and Drug Administration (FDA) will miss its deadline to approve Kalvista Therapeutics' experimental drug, sebetralstat, for hereditary angioedema, the company saeid Friday.
- The FDA informed Kalvista on Thursday that a decision on sebetralstat would not be issued by the June 17 deadline due to a "heavy workload and limited resources."...
- While drug reviews typically follow a six- to ten-month timeline after submission acceptance, recent downsizing at the FDA has raised concerns about the agency's ability to meet these...
The FDA is delaying its decision on kalvista Therapeutics’ sebetralstat, a potential new treatment for hereditary angioedema, due to pressing resource constraints. The agency missed its June 17 deadline, citing a heavy workload and limited staff, but anticipates a verdict within four weeks. This delay is not related to the drug’s clinical trial data, which showed positive results.News Directory 3 is following this story closely,as the FDA division overseeing sebetralstat also missed a deadline for GSK‘s Nucala,raising broader questions about the agency’s capacity. concerns grow about the ability of the FDA to keep to their timelines. The potential for a new oral alternative to injectable medications is promising. Discover what’s next with sebetralstat’s approval.
FDA Delays Kalvista Drug Decision Due to Resource Constraints
Updated June 17, 2025
The Food and Drug Administration (FDA) will miss its deadline to approve Kalvista Therapeutics‘ experimental drug, sebetralstat, for hereditary angioedema, the company saeid Friday. Kalvista cited “resource constraints” at the agency as the reason for the delay.
The FDA informed Kalvista on Thursday that a decision on sebetralstat would not be issued by the June 17 deadline due to a “heavy workload and limited resources.” Kalvista anticipates a verdict within approximately four weeks. The company emphasized that the delay is unrelated to any issues with the drug’s clinical trial results and that the FDA has not requested additional data. Finalizing the prescribing information is the only remaining step in the review process.
While drug reviews typically follow a six- to ten-month timeline after submission acceptance, recent downsizing at the FDA has raised concerns about the agency’s ability to meet these goals. Although drug reviewers were reportedly spared from layoffs,support staff reductions have impacted the process.
Other companies, including Novavax and GSK, have also reported unexpected delays in FDA decision-making. However, Kalvista said it was specifically told that limited agency resources caused its delay. The company stated it responded to all FDA requests promptly.
Leerink Partners analyst Joseph Schwartz noted that the FDA division reviewing sebetralstat also missed a deadline for GSK’s Nucala. This division is simultaneously reviewing another hereditary angioedema drug from CSL with the same June 17 deadline. Schwartz remains “confident in the eventual approval” of sebetralstat, attributing the delays to a heavy workload within that specific division.
Sebetralstat is designed as an oral alternative to injectable medications for hereditary angioedema. Clinical trials suggest it provides comparable symptom relief. Stifel analysts estimate peak U.S. sales of $600 million annually for Kalvista’s drug.
What’s next
Kalvista expects the FDA to make a decision on sebetralstat within the next four weeks, potentially adding a new oral treatment option for hereditary angioedema patients.